Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 1:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 123 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diabetic Neuralgia Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT00603265
View directory record Official record
Conditions
Peripheral Neuropathy, Neuropathic Pain
Interventions
ADL5859, Duloxetine, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Riverside, California • Torrance, California • Kissimmee, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Sep 7, 2026, 1:30 PM EDT
Not yet recruiting Phase 4 Interventional

Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy

NCT07795593
View directory record Official record
Conditions
Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies
Interventions
Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication
Device · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Stanford, California • Jacksonville, Florida • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 7, 2026, 1:30 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of ASCT-83 in Healthy Adults

NCT07363395
View directory record Official record
Conditions
Neuropathic Pain
Interventions
ASCT-83, Placebo
Drug
Lead sponsor
Alcamena Stem Cell Therapeutics
Industry
Eligibility
18 Years to 64 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 7, 2026, 1:30 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy

NCT00229437
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
TAK-128, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
40
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Sep 7, 2026, 1:30 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2a Study to Assess Safety & Pharmacokinetics of Sustained Release Sodium Nitrite in Patients With Diabetic Pain

NCT02412852
View directory record Official record
Conditions
Diabetes
Interventions
Sodium nitrite, Placebo
Drug
Lead sponsor
TheraVasc Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Centerville, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 7, 2026, 1:30 PM EDT
Terminated Phase 2 Interventional Results available

A Trial in Painful Diabetic Peripheral Neuropathy With GRT3983Y

NCT01056315
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
GRT3938Y, Placebo
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
61
States / cities
Fairhope, Alabama • Homewood, Alabama • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2019 · Synced Sep 7, 2026, 1:30 PM EDT
Completed Phase 2 Interventional Results available

A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).

NCT05620576
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
LY3857210, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
28
States / cities
Chandler, Arizona • Phoenix, Arizona • Riverside, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 7, 2026, 1:30 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

NCT06074562
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Mazisotine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
34
States / cities
Chandler, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 7, 2026, 1:30 PM EDT
Terminated Phase 2 Interventional

A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain

NCT01579279
View directory record Official record
Conditions
Diabetic Neuropathic Pain
Interventions
ABT-652 6 mg, ABT-652 12 mg, ABT-652 12 mg - 18 mg, Placebo, Duloxetine
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
8
States / cities
Anaheim, California • Walnut Creek, California • Milford, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2013 · Synced Sep 7, 2026, 1:30 PM EDT
Terminated Phase 2 Interventional

A 52-Week Study of Bicifadine in Patients With Chronic Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

NCT00597649
View directory record Official record
Conditions
Chronic Peripheral Neuropathy Pain in Diabetics
Interventions
Bicifadine
Drug
Lead sponsor
XTL Biopharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Paducah, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 29, 2009 · Synced Sep 7, 2026, 1:30 PM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)

NCT06696443
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Suzetrigine
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
65
States / cities
Anniston, Alabama • Daphne, Alabama • Scottsdale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 7, 2026, 1:30 PM EDT
Completed Phase 4 Interventional

A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain

NCT00904020
View directory record Official record
Conditions
Postherpetic Neuralgia, Diabetic Neuropathy, Low Back Pain
Interventions
Lidoderm
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
11
States / cities
Birmingham, Alabama • Phoenix, Arizona • Plantation, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 7, 2026, 1:30 PM EDT
Completed Not applicable Interventional Results available

Comparison of 10 kHz SCS Combined With CMM to CMM Alone in the Treatment of Neuropathic Limb Pain

NCT03228420
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
Senza HF10 Therapy, CMM
Device · Other
Lead sponsor
Nevro Corp
Industry
Eligibility
22 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Bradenton, Florida • Stockbridge, Georgia • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 7, 2026, 1:30 PM EDT
Completed Phase 2 Interventional Results available

Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy

NCT03176472
View directory record Official record
Conditions
Painful Diabetic Peripheral Neuropathy
Interventions
ricolinostat, Placebo
Drug
Lead sponsor
Regenacy Pharmaceuticals LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
35
States / cities
Anniston, Alabama • Phoenix, Arizona • Huntington Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 7, 2026, 1:30 PM EDT
Recruiting Phase 2 Interventional

A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

NCT05986292
View directory record Official record
Conditions
Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
Interventions
LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
62
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 7, 2026, 1:30 PM EDT
Completed Phase 2 Interventional

Study of the Safety, Tolerability and Efficacy of V3381 in Patients With Diabetic Peripheral Neuropathic Pain

NCT00794430
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
V3381, Placebo
Drug
Lead sponsor
Vernalis (R&D) Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Little Rock, Arkansas • Ocala, Florida • St. Petersburg, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Sep 7, 2026, 1:30 PM EDT
Withdrawn Not applicable Interventional

Exercise Induced Hypoalgesia Diabetes

NCT05296642
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain
Interventions
Moderate Cycling, Personalized Tourniquet System
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Sep 7, 2026, 1:30 PM EDT
Completed Phase 4 Interventional Results available

An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain

NCT00385671
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
duloxetine hydrochloride, pregabalin, gabapentin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
5
States / cities
Torrance, California • Cromwell, Connecticut • Staten Island, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Sep 7, 2026, 1:30 PM EDT
Completed Phase 2 Interventional

Diabetic Peripheral Neuropathic Pain (DPNP)

NCT01314222
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
BMS-954561, Pregabalin, Placebo matching BMS-954561, Placebo matching Pregabalin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Lomita, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced Sep 7, 2026, 1:30 PM EDT
Not listed Phase 3 Interventional

The Effects of the Magnetic Molecular Energizer (MME) on Diabetic Peripheral Neuropathy

NCT00134524
View directory record Official record
Conditions
Diabetic Neuropathies, Pain, Neuralgia
Interventions
MME procedure
Procedure
Lead sponsor
Advanced Magnetic Research Institute International
Industry
Eligibility
18 Years to 79 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
Tucson, Arizona • Sterling Heights, Michigan • Mocksville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2007 · Synced Sep 7, 2026, 1:30 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy

NCT00760955
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
TAK-583, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
33
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Sep 7, 2026, 1:30 PM EDT
Not listed Not applicable Interventional

An Evaluation of an SCCD on the Symptomatology of Painful DPN

NCT03331614
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
Flowaid FA-100 SCCD
Device
Lead sponsor
Rosenblum, Jonathan I., DPM
Individual
Eligibility
18 Years to 90 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lodi, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 7, 2026, 1:30 PM EDT
Not listed Phase 4 Interventional

Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy

NCT01770964
View directory record Official record
Conditions
Diabetes Mellitus, Painful Distal Symmetric Sensorimotor Polyneuropathy
Interventions
Pregabalin, placebo, Training Type A, Training Type B
Drug · Behavioral
Lead sponsor
Analgesic Solutions
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Brighton, Massachusetts • Watertown, Massachusetts • Johnson City, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 7, 2026, 1:30 PM EDT
Active, not recruiting Not applicable Interventional

Optimization of NIBS for Diabetic Neuropathy Neuropathic Pain

NCT03625752
View directory record Official record
Conditions
Diabetic Neuropathies, Chronic Pain
Interventions
Active Comparator: Active tDCS + Active TUS, Sham
Device
Lead sponsor
Case Western Reserve University
Other
Eligibility
40 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 7, 2026, 1:30 PM EDT